Skip to content
Open access

MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

Sep 2026 · Frontiers in Microbiology · Vol 17 · 0 citations · 119 references
Medicine

TL;DR

Multi-omics analyses across complementary in vitro and in vivo models suggest that MaaT013 modulates biological processes involved in aGvHD pathogenesis, providing exploratory, multi-model evidence of MaaT013's potential to mitigate aGvHD by restoring microbial diversity, gut integrity, and immune homeostasis.

Abstract

Background Acute graft-vs.-host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT), where allogeneic donor T cells recognize recipient tissues as foreign and damage them. Gut microbiota disruption following allo-HCT has been associated with increased aGvHD incidence, severity, and mortality. Growing clinical evidence suggests the efficacy of fecal microbiotherapy to restore a healthy and diverse gut microbiota and to treat aGvHD. MaaT013 (Xervyteg®), a standardized allogeneic fecal microbiotherapy derived from pooled healthy human fecal microbiota, has demonstrated efficacy in mitigating steroid-refractory aGvHD in the Phase 2 HERACLES trial, and is currently being evaluated in the pivotal ARES trial in ruxolitinib-resistant aGvHD with gastrointestinal involvement. Methods Here, multi-omics analyses across complementary in vitro and in vivo models suggest that MaaT013 modulates biological processes involved in aGvHD pathogenesis. Results First, MaaT013-derived metabolites prevented inflammation-induced gut barrier alteration in an in vitro leaky gut model. Second, MaaT013 stimulated dendritic cell-mediated Tregs amplification and subsequent release of IL-10 and TGF-b in vitro. Third, beneficial bacteria from MaaT013 engrafted in the gut of germ-free mice, producing anti-inflammatory metabolites and restoring healthy gut physiology through immune rebalancing. Finally, MaaT013 delayed the appearance of aGvHD symptoms in a specific-pathogen free xenogeneic mouse model of aGvHD. Discussion Together, these results provide exploratory, multi-model evidence of MaaT013's potential to mitigate aGvHD by restoring microbial diversity, gut integrity, and immune homeostasis.

Read PDF

Similar papers

Open access Sep 2026

Paeoniflorin prevents acute graft-versus-host disease while preserving graft-versus-tumor effects

Findings support PF as a potential prophylactic candidate for allo-HSCT through coordinated regulation of donor T cell responses, inflammatory mediators, hematopoietic reconstitution, intestinal barrier injury, apoptosis, and gut microbiota, while preserving GVT activity.

Xing-Yu Wan, Nan Li, Yang Gou et al. · 0 citations
Review Open access Sep 2026

Microbiome-Based Therapeutics in Oncology: Expanding Indications Beyond C. difficile

The intestinal microbiome has emerged as a clinically significant modulator of outcomes across multiple domains of cancer care. In hematopoietic stem cell transplantation (HSCT), loss of microbial diversity and depletion of short-chain fatty acid-producing commensals are independently associated with graft-versus-host...

Ayham Alomari, Abdallah Kheshman, Peter Morkos et al. · 0 citations
Review Sep 2026

Gut Microbiota in Kidney Transplantation: Mechanistic Insights and Implications for Precision Immunosuppression.

Kidney transplantation represents the optimal treatment for eligible patients with end-stage renal disease (ESRD), yet long-term graft survival remains threatened by rejection, infection, and immunosuppressant-related toxicity. Increasing evidence identifies the gut microbiome as an important modulator of these outcome...

Ya-Long Zhang, Rui Yan, Kang-Yu Wang et al. · 0 citations
Review Open access Aug 2026

Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma

Collectively, microbiome-based approaches may contribute to the development of personalized immunotherapeutic strategies in HCC, although larger standardized prospective studies are required before microbiome-derived biomarkers can be implemented in routine clinical practice.

Mădălina-Raluca Ostafe, S. Volovat, Ana Clement et al. · 0 citations
Review Open access Oct 2026

The gut microenvironment in antibody-mediated rejection: from conventional immunosuppression to precision immunomodulation in organ transplantation

The gut microbiota and broader gut microenvironment, comprising microbiota-derived metabolites and host–microbial interactions, have emerged as potentially modifiable factors associated with host immune regulation and have been implicated in altered drug responsiveness, immune-mediated diseases, and metabolic disorders...

Yoshiko Matsuda · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.